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The hemodynamic effects of nisoldipine were in- 
vestigated in 16 patients with suspected coronary 
artery disease who underwent routine cardiac 
catheterization. Nisoldipine was given intravenously 
in a dose of 6 pg/kg over 3 minutes and measure- 
ments made before and after drug administration 
during spontaneous and matched atrial paced heart 
rate. During sinus rhythm, nisoldipine produced a 
significant increase in heart rate (19%, p <10m5). 
Left ventricular systolic pressure decreased 28 % 
(p <10W6) and left ventricular end-diastolic pressure 
did not change significantly (5%, difference not 
significant). Coronary sinus and great cardiac vein 
blood flow increased by 21% (p <O-02) and 25 % 
(p <O.OOS), respectively, after nisoldipine admin- 
istratlon. Simultaneously, mean aortic pressure 
decreased 33% (p <10V6); consequently, the glo- 
bal and regional coronary vascular resistances 
decreased by 50 % (p <10P4). The decreases In 
global (-8%) and regional (-4%) myocardial 
oxygen consumption did not reach statistical sig- 
nificance. A 6% (not significant) increase in end- 
diastolic volume and an 11% (p <0.002) decrease 
in end-systolic volume resulted in an increase of 
21% in stroke volume (p <10m4) with a consistent 
increase in ejection fraction (-I- 16 %, p <10m5). 
Total systemic vascular resistance was reduced by 
30% (p <0.0002). During spontaneous heart rate 
and matched atrial pacing, the time constant of 
isovolumic relaxation as assessed by a biexpo- 
nential model, was significantly shortened. The 
maximal velocity of isovolumic contraction after 
nisoldipine was admlnistered remained higher 
(+I2 %, p <0.02) at an identical paced heart rate. 
Thus, nisoldipine is a potent coronary and peripheral 
vasodilator. No negative inotropic effects were ob- 
served in the dosage used. 
(Am J Cardiol 1985;56:140-146) 
Nisoldipine is a new dihydropyridine derivative, 
chemically similar to nifedipine and other related 
dihydropyridines.1-4 Despite its chemical similarity, its 
pharmacologic properties differ substantially from ni- 
fedipine. Although less potent in the inhibition of con- 
traction of isolated heart muscle, nisoldipine is 4 to 10 
times more potent in the inhibition of vascular smooth 
muscle contraction5 The main in vivo pharmacologic 
action of nisoldipine appears to be its inhibitory effect 
on vascular smooth muscle, particularly that of the 
coronary vasculature.5 The electrophysiologic effects 
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at concentrations producing such vascular changes are 
minimal.6 
The selectivity of nisoldipine for the coronary vas- 
cular bed may be of great significance in patients with 
coronary artery disease when imbalance in myocardial 
oxygen supply and demand is caused by increased tone 
of coronary vasculature. The present study was un- 
dertaken to investigate the effects of nisoldipine on 
peripheral and coronary vasculature and left ventricular 
(LV) function. 
Methods 
Sixteen patients who underwent investigation for chest pain 
and who were suspected of having coronary artery disease were 
studied at the time of cardiac catheterization. Eleven patients 
were men and mean age of the patients was 57 years (range 44 
to 69). Significant coronary artery disease was defined as at 
least 50% luminal diameter narrowing in at least 1 major ar- 
tery. Four patients had no significant coronary artery disease, 
and of these, 2 were subsequently diagnosed as having dilated 
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cardiomyopathy. No patient had clinical evidence of cardiac 
failure and only 2 patients had LV ejection fraction of less 
than 40%. Seven patients had had a previous myocardial in- 
farction. Patient data are summarized in Table I. 
Protocol Reta blockers, nitrams, c&&~ &tagccicti an,! 
digitalis were discontinued 36 hours before the study. Cardiac 
catheterization was performed with the patients fasting and 
without premeditation. A Bairn coronary sinus and great 
cardiac vein7 flow catheter or a Ganz coronary sinus flow 
thermodilution catheter was inserted into the coronary sinus 
through a right antecubital vein. Aortic or LV pressures were 
recorded with manometers mounted on a pigtail catheter. 
Heart rate, aortic and LV pressures, pressure-derived indexes 
of isovolumic contraction and relaxation (see later), thermo- 
dilution coronary sinus and great cardiac vein flows, and 
oxygen saturations obtained simultaneously from the aorta 
and coronary sinus could thus be measured. To assess hemo- 
dynamic changes independent of changes in heart rate, mea- 
surements were made during spontaneous heart rate and at 
matched atria1 paced rates. 
After establishing a control state the following protocol was 
followed: 
(1) LV cineangiography at a paced heart rate 15 beats more 
than the spontaneous heart rate was performed at 50 frames/s 
in a 30” right anterior oblique view with the injection of a 
nonionic contrast medium, which has been shown to have no 
effect on hemodynamic status.8 Care was taken to avoid a 
Valsalva maneuver. Stroke volume was calculated as the dif- 
ference between end-diastolic and end-systolic volumes. Si- 
multaneous LV pressures recordings were made. 
(2) At least 10 minutes after angiography and when spon- 
taneous heart rate and pressure values had returned to 
control, the pressure measurements were repeated during the 
same paced rate as used for angiography. Immediately after, 
the pressures, oxygen saturations and coronary venous flow 
measurements were performed during spontaneous heart 
rate. 
(3) Nisoldipine, 2 pg/kg/min, was then infused intrave- 
nously over 3 minutes. 
(4) Two minutes after nisoldipine was administered the 
measurements outlined in protocol 2 were repeated during the 
same atria1 paced rate and during spontaneous heart rate. 
(5) The LV cineangiography at the matched atria1 paced 
rate was then repeated with simultaneous LV pressure 
recording. 
(6) Coronary angiography was performed. 
Analysis of pressure-derived indexes during systole 
an8 diastole: Pressure measurements suitable for analysis 
before and after nisoldipine were obtained in 14 patients 
during spontaneous heart rate and 9 patients during paced 
heart rate. Pressure measurements during angiography were 
obtainable in each of the 15 patients with LV angiograms 
suitable for regional wall motion analysis. LV pressure was 
digitized at 250 samples/s. Peak LV pressure, LV end-diastolic 
pressure, peak positive dP/dt, peak negative dP/dt and the 
relation between dP/dt pressure and total pressure linearly 
extrapolated to pressure = 0 (Vmax) were computed on line 
after data acquisition of 20 seconds. 
determination of relaxation parameters: For off-line 
analysis of LV pressure relaxation, an updated version of the 
beat-to-beat program described previouslygJO was used with 
the following definitions: Pressure at the beginning of isovo- 
lumic relaxation (Pb) is the pressure at the point at which 
dP/dt is minimal (maximal negative dP/dt), and pressure at 
the end of isovolumetric relaxation (P,) is the pressure less 
than or equal to the previous end-diastolic pressure, but not 
less than 1 mm Hg. Although the latter definition may result 
in P, being measured just after mitral valve opening, esti- 
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LAD = left anterior descending coronary artery; LC = left circumflex 
artery; LM = left main stem; Ml = myocardial infarction; R = right 
coronary artery; + = present; 0 = absent; - = no. 
mation of the time constants by more stringent criteria, such 
as end-diastolic pressure + 10 mm Hg, did not result in a 
significantly better estimation, and failed to measure pressure 
during increased heart rates. The semilogarithmic model used 
for the off-line beat-to-beat calculation of the relaxation pa- 
rameters was: P(t) = P,e-tiT, where P is pressure; P, is 
equivalent to Pb when a true exponential decay is present 
starting from the time of peak negative dP/dt. The P, and T 
parameters were estimated from a linear least squares fit on 
1nP = -t/T + lnP,. In addition, a biexponential fit for iso- 
volumic relaxation was determined characterized by 2 expo- 
nential time constants; the fit for the first 40 ms (n = S), Tl, 
and the fit after the first 40 ms, T2 (n >-3).r1 
Coronary blood flow measurements and myocar~ia~ 
oxygen consumption: In 11 patients coronary sinus flow and 
in 10 of these 11 great cardiac vein in flows were measured by 
the continuous thermodilution method of Ganz. Arterial, 
coronary sinus and great cardiac vein blood samples were si- 
multaneously withdrawn to determine blood oxygen content. 
Global and regional myocardial oxygen consumption were 
calculated as the product of coronary blood flow and arter- 
iocoronary venous oxygen content differences. 
Regional and global coronary vascular resistances were 
derived from the ratio of mean aortic pressure to great cardiac 
vein or coronary sinus blood flows. 
Analysis of global and regional left ventricular func- 
tion: Global and regional LV function was studied from the 
LV angiogram with an automated hard-wired endocardial 
contour detector linked to a minicomputer.rz For each ana- 
lyzed tine frame, LV volume was computed according to 
Simpson’s rule. After the end-diastolic and end-systolic 
frames were identified, stroke volume, global ejection fraction 
and total cardiac index were determined. Figure 1A illustrates 
the end-diastolic and end-systolic contours as displayed by 
the analysis system. Analysis of LV systolic function included 
both isovolumic and ejection phases indexes (ejection fraction 
and mean circumferential fiber shortening rate). Systolic re- 
gional wall displacement is determined along a system of 20 
coordinates based on the pattern of actual endocardial wall 
motion in normal personsr3 and generalized as a mathematic 
expression amenable to automatic data processing.r4Js 
For each segment, segmental volume is computed from the 
local radius (R) and the height of each segment (l/10 of LV 
long-axis length) (L) according to the formula: 1/2&r R2L. 
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TABLE II lsovolumic Contraction and Relaxation Before and After Nisoldipine 
Before After 
Nisoldipine Nisoldipine A% 
P 
Value 
RR (ms) LP 741 f 27 741 f 28 868 140 69 97 -1: <0.%3 
Peak LVP (mm Hg) :P 160 f 35 120 f 23 -25 54 0 17 1 4 -%~~05 
-dP/dt (mm Hg s-l) :P 1,852 f 324 1,552 f 238 -16 <0.0005 
1,661 f. 306 1,471 f 289 -11 <O.OOB 
+ dP/dt (mm Hg s-l) EP 1,515 f 407 1,393 f 355 <0.005 
1,470 f 329 1,485 f 437 
77 
Vmax (s-l) LP 41 f4 46 f 8 +12 <o.E 
40 f 8 50f 12 +25 <0.0005 
T (ms) :P 47 f 6 43 f 8 9 7 4 9 -I”, <O.E 
TI 0-M :P 52 f 7 45 f 6 -13 <0.005 
55 f 9 46 f 8 -16 <0.0005 
TP O’W r;P 40 f 6 41 f 12 t2.5 4 5 2f IO -5 Ii: 
dP/dt = rate of change in left ventricular pressure; LVP = left ventricular pressure; NP = spontaneous 
heart rate (n = 14); NS = not significant; P = matched pacing (n = 9); RR = cycle length; T = global time 
constant from the “semilogarhythmic” model; T1 and T2 = biexponential fitting: T,--fit of first 40 ms, 
Tn--fit after 40 ms; Vmax = maximal velocity of contractile element shortening. 
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FIGURE 1. A, computer output showing the end-diastolic (EDV) and end-systolic (ESV) contours of the 30’ right anterior oblique left ventriculogram 
and the system of coordinates along which left ventricular segmental wall displacement is determined. The corresponding volume data, ejection 
fraction (EF) and other parameters are shown in the upper left corner. B, left ventricular end-diastolic cavity is separated into 20 half-slices, The 
volume of each half-slice is computed according to the given formula: i/2,,-nR2L. C, regional contribution to global ejection fraction is determined 
from the systolic decrease of volume of the half-slice that corresponds to a particular wall segment. The systolic volume change is mainly a con- 
sequence of the decrease of radius (R) of the half-slice. D, The shaded zones represent the tenth to the ninetieth percentiles area of the regional 
contribution to ejection fraction (CREF) values in normal persons. On the X axis, the CREF values of the anterior and inferoposterior wall areas 
are displayed (%), while on the Y axis the segment numbers of the anterior wall (1 to IO) and of the inferoposterior wall (11 to 20) are depicted. 
BSA = body surface area; HR = heart rate; L = left ventricular long-axis length. 
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When normalized for end-diastolic volume, the systolic seg- 
mental volume change can be considered a parameter of re- 
gional pump function (Fig. 1B). During systole this parameter 
expresbt2 ~~~~~~~~~~~~~~~ yLIv ., v_______--- “~-+~---l--+h~ -qnt&hlTtinn nf Q rp_pion to eiec- 
tion fraction (CREF)14 (Fig. lC). The s-um of the CREF values 
for all 20 segments equals to the global ejection fraction. 
The cross-hatched zones in Figure 1D represent the CREF 
values between the tenth and the ninetieth percentile, as de- 
termined in 20 normal persons. The segmental CREF values 
in the anterobasal (segments 1 to 5), anterolateral (segments 
5 to 9), apical (segments 9,10,19 and ZO), inferior (segments 
15 to 19) and posterobasal (segments 11 to 15) wall regions 
were analyzed. Interpretable LV angiograms were available 
in 15 patients, and a total of 300 segments were analyzed in 
these patients; 1 patient had normal wall motion pattern, 7 
patients had abnormal wall motion in the inferior region, 
4 patients in the anterior region and 3 in both regions 
(Fig. 2). 
Statistics: Results are expressed as mean f standard de- 
viation. Group data before and after nisoldipine were com- 
pared by a paired Student t test. A p value of 0.05 was con- 
sidered statistically significant. 
3 PATIENTS 
WITH ABNORMAL POST NISOLOIPINE 
ANTERIOR WALL MOTION B 10-K pB’cB”lils I cry 
posterior (%) onter1or (%) 
e 7 5 5 4 3 2 IO 4 
7 PATIENTS 
WITH ABNORMAL 
INFERIOR WALL MOT10 
4 PATIENTS 
RE NlSCLOIPINE 
WITH ABNORMAL ANTERIO POST NIEOLOiPLNE 
AND iNFERiOR WALL MOT10 g.cg 10-W pc.‘cB”‘119 PO”> 
Figaro 2. Left ventricular regional wall motion in 14 patients: 3 patients 
with abnormal anterior wall motion, 7 patients with abnormal inferior 
wall motion, and 4 patients with abnormal anterior and inferior wall 
motion. 
Results 
Measurements during spontaneous heart rate: 
During spontaneous heart rate nisoldipine produced a .^. .T 
signumant uecrei~b~ iA1 r;;;k ~yb2ic presswe and an 
increase in heart rate (Fig. 3). At the end of the infusion 
the mean changes were 42 mm Hg for the peak systolic 
pressure (-28%, p <10e6) and 13 beats (+19%, p <10M5) 
for heart rate. Although peak Vce remained unchanged, 
Vmax was significantly increased, from 40 f 8 to 47 f 
13 s-l (+ 18%, p <0.005). The end-diastolic pressure did 
not change (19 to 20 mm Hg). 
Five minutes after administration of nisoldipine the 
pressure-derived indexes related to the isovolumic re- 
laxation were studied at spontaneous heart rate in 14 
patients (Table II). In this subset of patients, LV sys- 
tolic pressure decreased 24% (p <10e5) and -dP/dt 
decreased 11% (p <0.005). The time constant of relax- 
ations was shortened. 
Coronary sinus blood flow increased from 146 f 40 
to 176 f 35 ml/min (p <0.02) 3 minutes after completion 
of nisoldipine infusion while the great cardiac vein flow 
increased significantly after nisoldipine, from 87 f 20 
to 109 f 24 ml/min (p <0.005). Simultaneously, the 
mean aortic pressure decreased from 107 f 20 to 72 f 
9 mm Hg (-33%, p <10d6); consequently the global and 
the regional coronary vascular resistance decreased, 
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FIGURE 3. Serial hemodynamic changes during acute administration 
of intravenous nisoldipine (mean f standard deviation, n = 16). EDP 
= left ventricular end-diastolic pressure; HR = heart rate; LVP = left 
ventricular peak systolic pressure; Pk Vce = peak velocity of contractile 
element; Vmax = maximal velocity of contractile element shortening. 
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TABLE III Myocardial Oxygen Consumption, Coronary TABLE IV Left Ventricular Performance at Matched Paced 
Flow and Resistance Before and After Heart Rate Before and After Nisoldipine 
Intravenous Nisoldipine Administration in 15 Patients 
Before After P Before After P 
Nisoldipine Nisoldipine A% Value Nisoldipine Nisoldipine % Value 
C”,flzw, \ml/min) 
146f 40 176f 35 +21 <0.02 
GCJLI;; (ml/min) 
87 f 20 109 f 24 +25 <0.005 
MVOs CS (ml/min) 
n= 11 15.1 f 4.8 13.9 f 3.2 -8 NS 
MVnOz r-S;V (mUmin) 
9.2 f 3.2 8.8 f 2.5 -4 NS 
(A;.zy),02 diff-(ml%) 
10 f 2 8fl -20 <0.002 
(AtzrX$ O2 diff (ml % ) 
10f 2 8fl -20 <0.005 
Mep-A;,P (mm Hg) 
107 f 20 72 f 9 -33 <10-s 
Re;isJ. F,S (mm Hg/ml/min) 
0.8 f 0.2 0.4 f 0.1 -50 <1O-4 
Resist. GCV (mm Hg/ml/min) 
EDVI (ml/m*) 87 f 30 92 f 34 +6 <0.08 
ESVI (ml/m2) 44 f 23 39 f 24 -11 <0.002 
SVI (ml/m2) 43zt 11 52 f 13 +21 <10-d 
EF (%) 51 f8 59 f 10 +I6 <IO+ 
CFSR (s-l) 0.7 f 0.1 0.9 f 0.2 +29 <0.0002 
Cl (liters min/m2) 3.4 f 0.9 4.3 f 1.2 $26 <IO+ 
Ao mean (mm Hg) 107 f 19 94 f 13 -12 <O.OOl 
SVR (dynes s cm-5) 1467 f 493 1033 f 362 -30 <0.0002 
Peak LVP (mm Hg) 161 f 29 127 f 20 -21 <0.00005 
A0 = aortic pressure; CFSR = mean circumferential fiber shortening 
rate; Cl = cardiac index; EDVI = end-diastolic volume index; EF = 
ejection fraction; ESVI = end-systolic volume index; LVP = left ven- 
tricular pressure; SW = stroke volume index; SVR = systemic vascular 
resistance. 
n = 10 1.4 f 0.2 0.7 f 0.1 -50 <10-d 
AoP = aortic pressure; Art. = arteriocoronary; CS = coronary sinus; 
GCV = great cardiac vein; MV02 = global (CS) or regional (GCV) 
myocardial oxygen consumption; NS = not significant; O2 diff = oxygen 
difference; Resist. = resistance. 
respectively, from 0.8 f 0.2 to 0.4 f 0.1 mm Hg/ml/min 
(p <10A4) and from 1.4 f 0.2 to 0.7 f 0.1 mm Hg/ml/ 
min (p <10W4) (Fig. 4, Table III). 
Although the mean arteriocoronary sinus and great 
cardiac vein oxygen difference decreased from 10 f 2 
and 10 f 2 to 8 f 1 (p <0.002) and 8 f 1 ml/l00 ml (p 
<0.005), respectively, the decrease in global (from 15 
f 5 to 14 f 3 ml/min) and regional (from 9 f 3 to 9 f 2 
ml/min) myocardial oxygen consumption (Table III) 
did not reach statistical significance. 
Measurements during matched paced heart rate: 
In a subset of 9 patients, 5 minutes after nisoldipine 
administration and at an identical paced heart rate 
(cycle length 741 f 27 vs 741 f 28 ms), the monoexpo- 
nential time constant was not significantly shortened; 
however, Tr, the first biexponential time constant was 
significantly shortened (Table II). After nisoldipine, 
Vmax remained significantly higher (+12%, p <0.02) 
at an identical paced heart rate. Table IV lists the 
change in LV volumes resulting from nisoldipine ad- 
ministration. A 6% (not significant) increase in end- 
diastolic volume and an 11% (p <O.OOZ) decrease in 
end-systolic volume resulted in a significant increase 
of 21% in systolic volume (from 43 f 11 to 52 f 13 
ml/m2, p <10W4) with a consistent increase in ejection 
fraction from 51 f 8 to 59 f 10% (+16%, p <10T5). Be- 
cause of this increase in cardiac output and reduction 
in blood pressure, total systemic vascular resistance was 
significantly reduced by 30% (from 1,467 f 493 to 1,033 
f 362 dynes cmW5). 
Ten minutes after the drug administration, at the 
time of the repeated LV angiogram, the peak LV pres- 
300 
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0 
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:i:t*+oL43 
0113 
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I 
FIGURE 4. Individual and mean 
changes in global (CS) and regional 
(GCV) coronary vascular resistance and 
blood flow after intravenous adminis- 
tration of nisoldipine. Values represent 
mean f standard deviation. RESIST CS 
= resistance calculated from coronary 
sinus blood flow; RESIST GCV = re- 
sistance calculated from great cardiac 
vein blood flow. 
x P e.02 
x ** 
P < ,005 P < 10-4 
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TABLE V Segments with Abnormal and Normal Contribution to Ejection Fraction 
(CREF) 
Segments with Abnormal Contribution 
to qectlon FraGiuu I 
No. of Segments Sum of CREF’ 
Before After Before After 
Segments with Normal Contribution 
+n FiPrtion fractian 
- 
No. of Segments Sum of CREF+ 
Before After Before After 
130 105 17 f 8 21 f8 170 195 33 f 13 36 f 14 
l p <0.02; + p <0.05. 
sure had increased back from 108 to 127 mm Hg, and the 
different time constants measured during the second 
LV angiogram were no longer significantly shortened 
(Table IV). 
From the regional wall displacement data, the CREF 
value was computed for each segment; 130 of 300 values 
were found abnormal, with a CREF value inferior to the 
tenth percentiles. Before administration of nisoldipine 
the sum of the CREF of these abnormal segments 
amounted to 17 f 8% of the global ejection fraction, 
whereas the normal segments contributed 33 f 13% to 
the ejection fraction (Table V). After nisoldipine ther- 
apy, 25 regions with functional impairment became 
normal and the sum of CREF values of these initially 
abnormal segments increased on average, from 17 f 8% 
to 21 f 8% (p <O.OOZ>, whereas the sum of CREF of the 
normal segments (n = 170) increased relatively less, 
from 33 f 13% to 36 Ifi 14% (p <0.05). The regional 
functional improvement of patients with inferior and 
anterior wall dysfunction is shown in Figure 2. 
Discussion 
Effect on coronary blood flow: The present study 
confirms in humans that nisoldipine is a potent 
coronary vasodilator: Coronary blood flow and great 
cardiac vein flows increased significantly 3 minutes 
after administration of nisoldipine. With the de- 
crease in mean aortic pressure, large calculated de- 
creases in global (-50%) and regional (-50%) coronary 
vascular resistances were observed. These results are 
consistent with previously reported data from animal 
studies, in which measurable responses in coronary 
sinus blood flow were found with a dose as low as 0.3 to 
0.5 pg/kg.4J” 
This increase in the coronary sinus flow was associ- 
ated with an increase in coronary sinus oxygen content, 
such that the calculated myocardial oxygen consump- 
tion did not decrease significantly. Of the main deter- 
minants of myocardial oxygen consumption, systolic 
and diastolic blood pressures were decreased while the 
isovolumic indexes of contractility, heart rate and stroke 
volume, were augmented, so that the myocardial oxygen 
consumption theoretically calculated according to the 
pressure work index of Rooke and Feigli7 was only 
slightly reduced (-12%, p <O.OZ). 
The general profile of the response to this compound 
is similar to that of nifedipine. It can generally be in- 
terpreted as the result of afterload reduction associated 
with sympathetic counterregulation.i8 In conscious 
dogs, additional 0 blockade significantly diminished the 
tachycardic effects but not the vasodilating actions of 
nisoldipine.5 The vasodilating action then is not a result 
of stimulation of vascular fl adrenoreceptors, but must 
be a result of direct action on vascular smooth muscle. 
Nisoldipine has been shown to be 10 times more potent 
than nifedipine in dilating the coronary system.4 
The decrease in total peripheral resistance (-30%) 
observed in our patients appears less pronounced than 
the vasodilating effect found in the coronary vasculature 
(-50%). This observation supports the hypothesis 
that the main vasodilating effect is on the coronary 
vasculature. 
Effect on the inotropic state: Nisoldipine appears 
in vitro to be equipotent to nifedipine in inhibiting 
contractions of the isolated heart and thus behaves as 
a typical calcium antagonist. However, because of the 
high vascular specificity, very low doses of the drug are 
pharmacologically effective without a major negative 
inotropic effect.5 Accompanying the decrease in after- 
load, the ejection as well as isovolumic indexes of con- 
tractility increased. This increase was not related to a 
change in heart rate since all the measurements were 
performed at a paced heart rate slightly above the 
spontaneous rhythm. This slight positive inotropic re- 
sponse may be explained by the sympathetic counter- 
regulation that triggers not only an increase in heart 
rate, but also a release of catecholamines.lg From the 
CREF values, our findings show that nisoldipine im- 
proves the function of hypokinetic segments at rest, 
because 25 of 130 chronically underperfused but non- 
infarcted areas demonstrated improvement in wall 
motion. It is doubtful that nisoldipine’s coronary 
vasodilating action was the main reason for the im- 
provement in ventricular function at rest. The im- 
provement probably resulted from the LV afterload 
reduction. 
Effect on isovolumic ~e~ax~tio~: IRecent experi- 
mental studies have underscored the role of the calcium 
influx-efflux mechanism in regulating the relaxation of 
the myocardial cell. 2o LV isovolumic relaxation time is 
often abnormally prolonged in patients with coronary 
artery disease leading to regional asynergy.sJ1>21 Ac- 
cording to previous reports,21722 this resting alteration 
in LV relaxation is probably due to the presence of fi- 
brotic scar tissue within still viable myocardium in 
which the biochemical processes of activation-con- 
traction-relaxation has been disturbed by chronic 
ischemia. Such increased stiffness is often seen after 
angina1 attacks. 
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In the present study, the isovolumic relaxation period 
was evaluated by using a biexponential model. At a 
paced heart rate, the intravenous administration of 
nisoldipine shortened some of the most sensitive in- 
dexes of isovolumic relaxation time, such as the time 
constant for the first 40 ms of the relaxation phase. 
Because it was demonstrated that myocardial ischemia 
leads to asynergy of wall motion, which can play a major 
role in altering the time course of the isovolumic pres- 
sure decrease,22,23 improvement of the asynergic zones 
may result in a more synchronous and rapid relaxation 
of the whole ventricle. 
Nisoldipine in this study did not produce any overt 
untoward effects, but hemodynamic changes occurred 
that would seem beneficial in the treatment of coronary 
artery disease. The effects of nisoldipine in a continuous 
infusion remains to be determined in patients with both 
normal and impaired LV function. Oral nisoldipine has 
already been investigated in patients with congestive 
heart failure where it reduces LV filling pressure and 
increases stroke volume index by simultaneously re- 
ducing cardiac pre- and afterload. The effect of 
nisoldipine on venous tone in this study is uncertain. 
There was no change in measured LV end-diastolic 
pressure; however, marked increases in cardiac output 
and thus venous return could have maintained LV 
end-diastolic pressure despite a decrease in venous tone. 
Direct assessment of venous tone (e.g., by forearm 
vascular capacitance) would be required to assess the 
relative venous vs arterial vasodilating effects of nisol- 
dipine. 
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